When a person suffers a traumatic brain injury or develops certain neurological conditions, it can lead to other secondary conditions that impact behavior and mental functions. These secondary conditions only serve to exacerbate the original trauma or condition.
Pharmaceutical companies are continuously formulating new drugs aimed at treating these conditions. But do they always have a patient’s best interest at heart? Or does profit trump patient well-being?
In the case of the prescription drug Nuedexta and its manufacturer Avanir Pharmaceuticals, it may be profit that is motivating the number of prescriptions being doled out to patients. The evidence for this may not lie in the millions of dollars in sales the company is raking in each year from its first-in-its-class drug, but the number of suspicious prescriptions and illegal kickbacks uncovered by a CNN investigation in 2017.